Literature DB >> 7492296

Myosin heavy-chain fragments and cardiac troponins in the serum in rhabdomyolysis. Diagnostic specificity of new biochemical markers.

M Löfberg1, R Tähtelä, M Härkönen, H Somer.   

Abstract

BACKGROUND: Myosin is the major structural protein in muscle. Antibodies to beta-type heavy meromyosin react with cardiac and slow-twitch skeletal muscle. Cardiac TnT and TnI were developed as tissue-specific indicators.
OBJECTIVES: To study myosin heavy-chain fragments as a delayed marker of previous rhabdomyolysis. To examine the cardiac specificity of cardiac troponin T (TnT) and cardiac troponin I (TnI) in patients with severe skeletal muscle damage. DESIGN AND METHODS: Serum myosin heavy-chain fragments, TnT, and TnI were studied up to 12 days after diagnosis in relationship to the serum creatine kinase level in 20 patients with rhabdomyolysis. The mean peak serum creatine kinase activity was 91,300 U/L. Myosin heavy-chain fragments were measured by an immunoradiometric assay, TnT by a one-step immunoenzymometric assay, and TnI by an immunoenzymometric assay.
RESULTS: Values for serum myosin heavy-chain fragments were greater than the upper limit of normal in all patients. The peak value (70 times the upper normal limit, on average) was usually achieved 4 to 7 days after the diagnosis of rhabdomyolysis, and it was increased up to 12 days. The peak level of TnT was increased in 95% of the patients, and it correlated strongly with the peak activity of serum creatine kinase. The highest TnI value was above the detection limit of myocardial infarction in 30% of the patients. Half of these patients were the only patients with ischemic changes observed on an electrocardiogram performed on admission to the hospital.
CONCLUSIONS: The measurement of myosin heavy-chain fragments was useful in the diagnosis of previous rhabdomyolysis up to 12 days. The role of TnT was negligible as an indicator of cardiac muscle damage in patients with severe rhabdomyolysis. Cardiac TnI is a more tissue-specific marker for myocardial damage even with concurrent rhabdomyolysis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7492296     DOI: 10.1001/archneur.1995.00540360090020

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  10 in total

1.  Molecular interaction site on procoagulant myosin for factor Xa-dependent prothrombin activation.

Authors:  Hiroshi Deguchi; Zihan Guo; Mohammed Hayat; Elsa Pflimlin; Sam Lear; Weijun Shen; John H Griffin
Journal:  J Biol Chem       Date:  2019-09-03       Impact factor: 5.157

2.  Circulating cardiac troponin I in trauma patients without cardiac contusion.

Authors:  A R Edouard; J F Benoist; C Cosson; O Mimoz; A Legrand; K Samii
Journal:  Intensive Care Med       Date:  1998-06       Impact factor: 17.440

3.  Plasma skeletal muscle myosin phenotypes identified by immunoblotting are associated with pulmonary embolism occurrence in young adults.

Authors:  Taichi K Deguchi; Hiroshi Deguchi; Zihan Guo; Darlene J Elias; John H Griffin
Journal:  Thromb Res       Date:  2020-02-27       Impact factor: 3.944

4.  Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey.

Authors:  Arthur R de Meijer; Bernard G Fikkers; Marinus H de Keijzer; Baziel G M van Engelen; Joost P H Drenth
Journal:  Intensive Care Med       Date:  2003-05-24       Impact factor: 17.440

Review 5.  Novel blood coagulation molecules: Skeletal muscle myosin and cardiac myosin.

Authors:  Hiroshi Deguchi; Shravan Morla; John H Griffin
Journal:  J Thromb Haemost       Date:  2020-10-25       Impact factor: 5.824

6.  Prothrombotic skeletal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va.

Authors:  Hiroshi Deguchi; Ranjeet K Sinha; Patrizia Marchese; Zaverio M Ruggeri; Jevgenia Zilberman-Rudenko; Owen J T McCarty; Mitchell J Cohen; John H Griffin
Journal:  Blood       Date:  2016-07-15       Impact factor: 22.113

7.  New considerations on pathways involved in acute traumatic coagulopathy: the thrombin generation paradox.

Authors:  Cedric Gangloff; Fanny Mingant; Michael Theron; Hubert Galinat; Ollivier Grimault; Yves Ozier; Karine Pichavant-Rafini
Journal:  World J Emerg Surg       Date:  2019-12-12       Impact factor: 5.469

8.  Skeletal muscle myosin promotes coagulation by binding factor XI via its A3 domain and enhancing thrombin-induced factor XI activation.

Authors:  Shravan Morla; Hiroshi Deguchi; Jevgenia Zilberman-Rudenko; András Gruber; Owen J T McCarty; Priyanka Srivastava; David Gailani; John H Griffin
Journal:  J Biol Chem       Date:  2022-01-07       Impact factor: 5.157

9.  Full-length plasma skeletal muscle myosin isoform deficiency is associated with coagulopathy in acutely injured patients.

Authors:  Julia R Coleman; Hiroshi Deguchi; Taichi K Deguchi; Mitchel J Cohen; Ernest E Moore; John H Griffin
Journal:  J Thromb Haemost       Date:  2022-03-20       Impact factor: 16.036

10.  Skeletal muscle myosin and cardiac myosin attenuate heparin's antithrombin-dependent anticoagulant activity.

Authors:  Shravan Morla; Hiroshi Deguchi; John H Griffin
Journal:  J Thromb Haemost       Date:  2020-12-10       Impact factor: 5.824

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.